Clinical trials: Impairment
Renal Impairment
Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419
The study is a two-center, Phase 1, open-label, single-dose, one-period, four groups, PK study in subjects with various severities of renal impairment and matched healthy controls.
- Trial name
- NCT05412472
- Testing
- GC4419
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Reflux, Renal Excretion
Renal Impairment Study
The purpose of this study is to see how quickly AZD3355 is taken up in to the blood and leaves the blood in people with normal kidney function or with different degrees of reduced kidney function.
- Trial name
- NCT00863161
- Testing
- AZD3355
- Where
- 3 sites in Sweden
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cognitive Dysfunction
Flutemetamol F 18 Injection Formulation Comparison
VIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other…
- Trial name
- NCT07873463
- Testing
- GE-287, Vizamyl
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- GE Healthcare
Advanced Cancer, Hepatic Impairment
Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.
- Trial name
- NCT00621725
- Testing
- AZD2171
- Where
- 3 sites in Denmark, Netherlands
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Hepatic Insufficiency, Liver Diseases
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.
- Trial name
- NCT07559474
- Testing
- INCB123667
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Diabetes, Hypertension
Real-world Aliskiren Use in Diabetic Patients
The purpose of this study is to evaluate real-world patterns of aliskiren use with a focus of change in renal function following aliskiren initiation as well as to identify "triggering events" that lead to aliskiren initiation.
- Trial name
- NCT01393860
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Novartis
Mild Cognitive Impairment
Digital Therapeutics Research on Efficiency About Mild Cognitive Impairment Study
The purpose of this study is to evaluate the efficiency and safety of a digital therapeutics(ET-101) for mild cognitive impairment (MCI). This is a randomized, sham-controlled, assessor-blinded, 24-week parallel study.
- Trial name
- DREAM (NCT05938426)
- Testing
- ET-101
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Emocog Inc.
Hepatic Impairment
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants
This was a Phase 1, open-label study to evaluate the PK, safety, and tolerability after administration of multiple doses of remibrutinib in participants with mild, moderate, or severe hepatic impairment (HI) compared to pooled…
- Trial name
- NCT05753592
- Testing
- Part 1; LOU064 (Remibrutinib), Part 2; LOU064 (Remibrutinib)
- Where
- Hungary
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment
To evaluate the pharmacokinetic characteristics of pyroglutamate rongliflozin capsules in type 2 diabetic subjects with normal renal function and mild to moderate renal impairment.
- Trial name
- NCT05374343
- Testing
- pyroglutamate rongliflozin capsules
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Renal Impairment
A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers
This is a study to compare AZD4831 pharmacokinetic (PK) parameters between participants with severe renal impairment and matched healthy volunteers following a single dose administration.
- Trial name
- NCT04949438
- Testing
- AZD4831
- Where
- Bulgaria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cognitive Decline, Mild Cognitive Impairment
The Effects of Chicken Extract and a Peptide Supplement for the Prevention of Cognitive Decline in Non-demented Elderly Adults
This trial investigates the effect of a chicken extract supplement and a peptide supplement on cognitive function and potential mechanisms of action of cognitive decline during ageing, among non-demented elderly adults using a…
- Conditions
- Cognitive Decline, Mild Cognitive Impairment, Aging
- Trial name
- NCT04555655
- Testing
- Chicken extract supplement, Peptide Supplement
- Where
- 3 sites in Taiwan
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Brand's Suntory Asia
Healthy, Renal Impairment
A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment
A phase 1 clinical trial to evaluate safety, PK/PD profiles and food effects of URC102 in patients with renal impairment and healthy people.
- Trial name
- NCT05198778
- Testing
- URC102
- Where
- 2 sites in South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Renal Impairment
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
- Trial name
- NCT06496217
- Testing
- MBX 2109
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- MBX Biosciences
Type 2 Diabetes Mellitus
A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease
The purpose of this study is to evaluate the efficacy and safety of trelagliptin when administered at a dose of 25 mg once weekly using placebo as a control in patients with type 2 diabetes mellitus complicated by severe renal…
- Trial name
- NCT02512068
- Testing
- Trelagliptin 25 mg
- Where
- 49 sites in Japan
- Volunteers
- 107 people
- Sponsor
- Takeda
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease…
- Trial name
- OLIMPIC (NCT02034006)
- Testing
- Ranibizumab
- Where
- 31 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Renal Impairment
Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543
This is an open-label, single-dose, sequentially designed, single-period study to determine the effect of moderate renal impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a…
- Trial name
- NCT05468749
- Testing
- CTP-543
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Concert Pharmaceuticals
Subjects With Impaired Renal Function and Healthy Subjects
A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function
The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function.
- Trial name
- NCT04414852
- Testing
- Apatinib Mesylate
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pharmacokinetics, Hepatic Insufficiency
Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)
Evaluate the potential effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of BAY 1841788 (ODM-201).
- Conditions
- Pharmacokinetics, Hepatic Insufficiency, Renal Insufficiency
- Trial name
- NCT02894385
- Testing
- BAY1841788
- Where
- 2 sites in Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Bayer
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Pevonedistat is a medicine to treat people with blood cancers or solid tumors. The main aim of the study is to learn about the levels of pevonedistat in the blood of participants with blood cancers or solid tumors, who also have…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency
- Trial name
- NCT03814005
- Testing
- Azacitidine, Pevonedistat
- Where
- 8 sites in United States, Spain
- Volunteers
- 17 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.